GR1803 Injection

GR1803 · Genrix (Shanghai) Biopharmaceutical Co., Ltd.

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for GR1803 Injection, covering 2025-07-29 to 2026-03-25. Get the full timeline:

Most recent: Clinical Trial Update: A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma [Phase 3]

See pricing